他汀类药物联合苯扎贝特对急性冠状动脉综合征患者的调脂疗效与安全性

Efficacy and Safety of Statins and Bezafibrate in the Treatment of Patients with Acute Coronary Syndrome

目的:研究并探讨他汀类药物联合苯扎贝特对急性冠状动脉综合征(ACS)患者的调脂疗效及安全性。方法:于2014年1月至2016年12月期间,选取108例ACS患者随机分为两组,每组各54例,对照组采用他汀类药物治疗,观察组采用他汀类药物联合苯扎贝特治疗,治疗3个月后,比较两组患者的临床疗效、血脂水平、炎性因子指标、不良反应发生率、肝肾功能指标及心肌功能指标。结果:观察组的总有效率明显高于对照组(P<0.05);两组治疗后的血脂水平较治疗前均明显改善(P<0.05),其总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)均下降,高密度脂蛋白胆固醇(HDL-C)均增高,而在治疗后,观察组的TC、TG、LDL-C均明显低于对照组(P<0.05),HDL-C明显高于对照组(P<0.05);两组患者治疗后的C反应蛋白(CRP)、白介素6(IL-6)等炎性因子指标均较治疗前明显下降(P<0.05),而治疗后组间比较,观察组的CRP、IL-6均低于对照组(P<0.05);观察组与对照组的不良反应发生率分别为5.56%、9.26%,差异无统计学意义(P>0.05);治疗后,两组肝肾功能指标、心肌功能指标较治疗前均未发生明显变化(P>0.05)。结论:在ACS患者的临床治疗中,采用他汀类药物与苯扎贝特联合治疗具有显著的调脂疗效,且其安全性可靠。

Objective:To investigate the efficacy and safety of statins combined with bezafibrate in patients with acute coronary syndrome(ACS).Methods:From January2014to December2016,108cases of patients with acute coronary syndrome were selected and randomly divided into two groups,each group had54cases,the control group was treated with statins,the observation group was treated with statins and bezafibrate.After3months of treatment,the clinical efficacy,blood lipid level,inflammatory factor index,adverse reaction rate,liver and kidney function index and myocardial function index were compared between two groups.Results:The total effective rate in the observation group was significantly higher than the control group(P<0.05);the serum lipid levels in two groups after treatment were significantly improved than before treatment(P<0.05),total cholesterol(TC),triglyceride(TG)and low density lipoprotein cholesterol(LDL-C)were decreased,and high density lipoprotein cholesterol(HDL-C)were increased,while after treatment,TC,TG and LDL-C in the observation group were significantly lower than the control group(P<0.05),HDL-C was significantly higher than the control group(P<0.05);C reaction protein(CRP),interleukin6(IL-6)and other inflammatory factors in two groups after treatment were significantly decreased compared with before treatment(P<0.05),and the comparison between the two groups after treatment,CRP and IL-6in the observation group were lower than the control group(P<0.05);the adverse reactions rate in the observation group and the control group were respectively5.56%and9.26%,the difference was not statistically significant(P>0.05);after treatment,the liver and renal function indexes and myocardial function indexes in the two groups did not change significantly(P>0.05).Conclusion:In the clinical treatment of patients with acute coronary syndrome,the combination of statins and bezafibrate has significant lipid-lowering efficacy,and its safety is reliable.